top of page
Add a Title
feedbackText
⏱️ 320s
🌱 Beginner Level — 0 / 60
Prostate Cancer — Castration-Resistant Therapy Sequencing
A 72-year-old man with mCRPC progresses after ADT + abiraterone. ECOG 1.
summaryTitle
summaryScore
summaryRefs
sfx_miss_firm
00:00 / 00:00
sfx_correct_minimal
00:00 / 00:00
sfx_complete_fanfare
00:00 / 00:00
💡 Hint: Correct order adjusted to match available steps.
Confirm castrate testosterone (<50 ng/dL) with progression
Cabazitaxel if progression after docetaxel and AR-targeted therapy
PSMA-PET positive → 177Lu-PSMA-617 radioligand therapy
Give docetaxel chemotherapy if not previously used
Avoid sequential AR-targeted therapy alone (abiraterone → enzalutamide) after progression
Olaparib/rucaparib if BRCA1/2 or ATM mutation
bottom of page